Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target.

A fundamental structural event in the progression of heart failure due to dilated cardiomyopathy is left ventricular (LV) myocardial remodeling. The matrix metalloproteinases (MMPs) are an endogenous family of enzymes which contribute to matrix remodeling in several disease states. The goal of this report is to summarize recent findings regarding the myocardial MMP system and the relation to matrix remodeling in the failing heart. In both experimental and clinical forms of dilated cardiomyopathy (DCM), increased expression of certain species of myocardial MMPs have been demonstrated. Specifically, increased myocardial levels of the gelatinase, MMP-9 has been identified in both ischemic and non-ischemic forms of human DCM. In addition, stromelysin or MMP-3 increased by over four-fold in DCM. The increased levels of MMP-3 in DCM may have particular importance since this MMP degrades a wide range of extracellular proteins and can activate other MMPs. In normal human LV myocardium, the membrane type 1 MMP (MT1-MMP) was detected. These MT-MMPs may provide important sites for local MMP activation within the myocardium. In a pacing model of LV failure, MMP expression and activity increased early and were temporally associated with LV myocardial matrix remodeling. Using a broad-spectrum pharmacological MMP inhibitor in this pacing model, the degree of LV dilation was attenuated and associated with an improvement in LV pump function. Thus, increased LV myocardial MMP expression and activity are contributory factors in the LV remodeling process in cardiomyopathic disease states. Regulation of myocardial MMP expression and activity may be an important therapeutic target for controlling myocardial matrix remodeling in the setting of developing heart failure.

[1]  Z. Galis,et al.  Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. , 1998, American journal of physiology. Heart and circulatory physiology.

[2]  P. Libby,et al.  Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. , 1994, Circulation research.

[3]  A. Rowan,et al.  Prevention of cartilage breakdown by matrix metalloproteinase inhibition--a realistic therapeutic target? , 1998, British journal of rheumatology.

[4]  M. Zile,et al.  Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. , 1991, The American journal of physiology.

[5]  K. Weber,et al.  Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.

[6]  P. Armstrong,et al.  Fibrillar collagen and remodeling of dilated canine left ventricle. , 1990, Circulation.

[7]  S. Shapiro,et al.  Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  G. Murphy,et al.  Membrane-Type Matrix Metalloproteinases and Cell Surface-Associated Activation Cascades for Matrix Metalloproteinases , 1998 .

[9]  W. Marks,et al.  Decreased tissue inhibitor of metalloproteinases (TIMP) in abdominal aortic aneurysm tissue: a preliminary report. , 1991, The Journal of surgical research.

[10]  A. D. White,et al.  Emerging Therapeutic Advances for the Development of Second Generation Matrix Metalloproteinase Inhibitors , 1997, Current Pharmaceutical Design.

[11]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[12]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[13]  M. Fini,et al.  Regulation of Matrix Metalloproteinase Gene Expression , 1998 .

[14]  W. Parks,et al.  Collagen-stimulated induction of keratinocyte collagenase is mediated via tyrosine kinase and protein kinase C activities. , 1994, The Journal of biological chemistry.

[15]  W. Parks,et al.  Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. , 1996, Journal of vascular surgery.

[16]  Y. Okada,et al.  Cell surface binding and activation of gelatinase A induced by expression of membrane‐type‐1‐matrix metalloproteinase (MT1‐MMP) , 1996, FEBS letters.

[17]  A. Luttun,et al.  Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure , 1999, Nature Medicine.

[18]  J. Westermarck,et al.  Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. , 1996, European journal of biochemistry.

[19]  H. Currey.  Textbook of Rheumatology , 1985 .

[20]  R. Mecham,et al.  Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. , 1995, The Journal of clinical investigation.

[21]  J. Greene,et al.  Molecular Cloning and Characterization of Human Tissue Inhibitor of Metalloproteinase 4* , 1996, The Journal of Biological Chemistry.

[22]  J. Díez,et al.  Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. , 1995, Circulation.

[23]  S. Frisch,et al.  Positive and negative transcriptional elements of the human type IV collagenase gene , 1990, Molecular and cellular biology.

[24]  F. Spinale,et al.  Defects in Matrix Metalloproteinase Inhibitory Stoichiometry and Selective MMP Induction in Patients with Nonischemic or Ischemic Dilated Cardiomyopathy , 1999, Annals of the New York Academy of Sciences.

[25]  F. Spinale,et al.  Increased Matrix Metalloproteinase Activity and Selective Upregulation in LV Myocardium From Patients With End-Stage Dilated Cardiomyopathy , 1998 .

[26]  J. S. Janicki,et al.  Inadequate collagen tethers in dilated cardiopathy. , 1988, American heart journal.

[27]  L. Vaca,et al.  Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. , 1993, The Journal of clinical investigation.

[28]  J. Cohn,et al.  Prognostic Significance of Serial Changes in Left Ventricular Ejection Fraction in Patients With Congestive Heart Failure , 1993, Circulation.

[29]  Jian-Dong Li,et al.  Tumor‐derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38 , 1998, FEBS letters.

[30]  B. Mason,et al.  Potent and selective inhibitors of gelatinase-a 1. hydroxamic acid derivatives , 1994 .

[31]  G. Butler,et al.  Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases. , 1997, European journal of biochemistry.

[32]  P. Soloway,et al.  Pattern of messenger ribonucleic acid expression of tissue inhibitors of metalloproteinases (TIMPs) during testicular maturation in male mice lacking a functional TIMP-1 gene. , 1998, Biology of reproduction.

[33]  M. Zile,et al.  Relation between ventricular and myocyte remodeling with the development and regression of supraventricular tachycardia-induced cardiomyopathy. , 1991, Circulation research.

[34]  D. Garcia-Dorado,et al.  Cardiovascular Research , 1966 .

[35]  S. Nagataki,et al.  TNF‐α‐mediated expression of membrane‐type matrix metalloproteinase in rheumatoid synovial fibroblasts , 1996, Immunology.

[36]  S. Whitebread,et al.  Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes. , 1997, Circulation.

[37]  M. Zile,et al.  Changes in left ventricular volume, mass, and function during the development and regression of supraventricular tachycardia-induced cardiomyopathy. Disparity between recovery of systolic versus diastolic function. , 1990, Circulation.

[38]  A. Eisen,et al.  Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Shapiro,et al.  Mighty mice: transgenic technology "knocks out" questions of matrix metalloproteinase function. , 1997, Matrix biology : journal of the International Society for Matrix Biology.

[40]  F. Clubb,et al.  Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. , 1998, Circulation.

[41]  F. Spinale,et al.  Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. , 1998, Circulation research.

[42]  D. Mann,et al.  Mechanisms and models in heart failure: A combinatorial approach. , 1999, Circulation.

[43]  M. Munger,et al.  Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1996, The American journal of cardiology.

[44]  J. Woessner,et al.  Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. , 1996, The American journal of pathology.

[45]  M. Foley,et al.  Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues. , 1994 .

[46]  A. Newby,et al.  Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. , 1996, The Biochemical journal.

[47]  W. Hagmann,et al.  Inhibition of stromelysin-1 (MMP-3) by peptidyl phosphinic acids , 1994 .

[48]  M. Zile,et al.  Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function. , 1999, Circulation research.

[49]  L. Mann,et al.  Mechanisms and Models in Heart Failure , 1999 .

[50]  P. McCann,et al.  Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. , 1997, Pharmacology & therapeutics.

[51]  H. Eichler,et al.  Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. , 1995, The American journal of cardiology.

[52]  B. Toole,et al.  Stimulation of Matrix Metalloproteinase Production by Recombinant Extracellular Matrix Metalloproteinase Inducer from Transfected Chinese Hamster Ovary Cells* , 1997, The Journal of Biological Chemistry.

[53]  A. Schönthal,et al.  Requirement for fos gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters , 1988, Cell.

[54]  Jennifer D. Walker,et al.  Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy. Effects on left ventricular and myocyte structure and function. , 1995, Circulation.

[55]  C. López-Otín,et al.  Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. , 1994, The Journal of biological chemistry.

[56]  Y. Sun,et al.  Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. , 1998, Circulation.

[57]  W. Mckenna,et al.  Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives. , 1995, Heart.

[58]  H. Nagase.  Activation mechanisms of matrix metalloproteinases. , 1997, Biological chemistry.

[59]  N. Sharpe.  Cardiac Remodeling in Congestive Heart Failure , 1994 .

[60]  M. Zile,et al.  Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry. , 1999, The Journal of pharmacology and experimental therapeutics.

[61]  T. Borg,et al.  Interaction of the extracellular matrix with cardiac myocytes during development and disease , 1990 .

[62]  W. Frishman,et al.  Matrix Metalloproteinases and Coronary Artery Disease: A Novel Therapeutic Target , 1997, Journal of clinical pharmacology.

[63]  D. Brenner,et al.  Prolonged activation of jun and collagenase genes by tumour necrosis factor-α , 1989, Nature.

[64]  J. Covell,et al.  Increase in Cross‐Linking of Type I and Type III Collagens Associated With Volume‐Overload Hypertrophy , 1988, Circulation research.

[65]  H. Nagase.  Stromelysins 1 and 2 , 1998 .

[66]  S. Whitebread,et al.  Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems. , 1997, Circulation.

[67]  D. Hupe,et al.  A recombinant human stromelysin catalytic domain identifying tryptophan derivatives as human stromelysin inhibitors. , 1994, Journal of medicinal chemistry.

[68]  J. McEwan,et al.  Matrix metalloproteinases and cardiovascular disease. , 1995, Circulation research.

[69]  J. Smyth,et al.  Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[70]  P. Libby,et al.  Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. , 1999, Circulation.